| First Author | Kenigsbuch M | Year | 2022 |
| Journal | Nat Neurosci | Volume | 25 |
| Issue | 7 | Pages | 876-886 |
| PubMed ID | 35760863 | Mgi Jnum | J:335650 |
| Mgi Id | MGI:7482089 | Doi | 10.1038/s41593-022-01104-7 |
| Citation | Kenigsbuch M, et al. (2022) A shared disease-associated oligodendrocyte signature among multiple CNS pathologies. Nat Neurosci 25(7):876-886 |
| abstractText | Alzheimer's disease (AD) is a complex neurodegenerative disease, perturbing neuronal and non-neuronal cell populations. In this study, using single-cell transcriptomics, we mapped all non-immune, non-neuronal cell populations in wild-type and AD model (5xFAD) mouse brains. We identified an oligodendrocyte state that increased in association with brain pathology, which we termed disease-associated oligodendrocytes (DOLs). In a murine model of amyloidosis, DOLs appear long after plaque accumulation, and amyloid-beta (Abeta) alone was not sufficient to induce the DOL signature in vitro. DOLs could be identified in a mouse model of tauopathy and in other murine neurodegenerative and autoimmune inflammatory conditions, suggesting a common response to severe pathological conditions. Using quantitative spatial analysis of mouse and postmortem human brain tissues, we found that oligodendrocytes expressing a key DOL marker (SERPINA3N/SERPINA3 accordingly) are present in the cortex in areas of brain damage and are enriched near Abeta plaques. In postmortem human brain tissue, the expression level of this marker correlated with cognitive decline. Altogether, this study uncovers a shared signature of oligodendrocytes in central nervous system pathologies. |
